<DOC>
	<DOCNO>NCT00939731</DOCNO>
	<brief_summary>The study open-label , randomize , 2-period , 2-treatment , 2-sequence , cross-over , single-dose study employ administration two PF-02341066 formulation fast state healthy adult volunteer .</brief_summary>
	<brief_title>Relative Drug Exposures Of Two Formulations PF-02341066</brief_title>
	<detailed_description />
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Healthy male and/or female nonchildbearing potential subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead electrocardiogram ( ECG ) clinical laboratory test ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . Pregnant nursing female ; female childbearing potential , include tubal ligation . To consider enrollment , woman 45 55 year age postmenopausal ( define amenorrheic least 2 year ) must confirmatory Folliclestimulating hormone ( FSH ) test result Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>bioavailability , capsule , tablet , healthy volunteer</keyword>
</DOC>